Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	767 people 3 RCTs in this analysis	Use of anticholinergic medication with paliperidone (3–15 mg/day) with placebo Absolute results not reported	RR 1.33 95% CI 1.00 to 1.78		Not significant
Systematic review	508 people 2 RCTs in this analysis	Decreased salivation with paliperidone (6–12 mg/day) with placebo Absolute results not reported	RR 4.12 95% CI 0.96 to 17.73		Not significant
Systematic review	793 people 2 RCTs in this analysis	Increased salivation with paliperidone (6–12 mg/day) with placebo Absolute results not reported	RR 5.41 95% CI 1.30 to 22.42	Large effect size	placebo
Systematic review	156 people 2 RCTs in this analysis	Hypertension with paliperidone with placebo Absolute results not reported	RR 2.27 95% CI 0.39 to 13.35		Not significant
Systematic review	605 people 2 RCTs in this analysis	Hypotension with paliperidone with placebo Absolute results not reported	RR 4.66 95% CI 0.89 to 24.46		Not significant
Systematic review	683 people 3 RCTs in this analysis	Prolonged QTc LD with paliperidone with placebo Absolute results not reported	RR 2.19 95% CI 0.48 to 9.96		Not significant
Systematic review	1638 people 5 RCTs in this analysis	Tachycardia with paliperidone with placebo Absolute results not reported	RR 1.88 95% CI 1.28 to 2.76	Small effect size	placebo
Systematic review	216 people Data from 1 RCT	Mean difference in change from baseline in QTc LD (ms) with paliperidone (6 mg/day) with placebo Absolute results not reported	Mean difference 1.50 ms 95% CI 1.12 ms to 1.88 ms	Effect size not calculated	placebo
Systematic review	216 people Data from 1 RCT	Mean difference in change from baseline in QTc LD (ms) with paliperidone (12 mg/day) with placebo Absolute results not reported	Mean difference –1.80 ms 95% CI –2.16 ms to –1.44 ms	Effect size not calculated	paliperidone
Systematic review	877 people 5 RCTs in this analysis	Mean difference in change from baseline in cholesterol (mmol/L) with paliperidone with placebo Absolute results not reported	Mean difference 0.12 mmol/L 95% CI 0.00 mmol/L to 0.24 mmol/L		Not significant
Systematic review	1876 people 6 RCTs in this analysis	Agitation or aggression with paliperidone with placebo Absolute results not reported	RR 0.64 95% CI 0.44 to 0.95	Small effect size	paliperidone
Systematic review	1918 people 7 RCTs in this analysis	Insomnia with paliperidone with placebo Absolute results not reported	RR 0.89 95% CI 0.69 to 1.15		Not significant
Systematic review	1715 people 5 RCTs in this analysis	Sleepiness with paliperidone with placebo Absolute results not reported	RR 1.50 95% CI 1.03 to 2.17	Small effect size	placebo
Systematic review	352 people 2 RCTs in this analysis	Fatigue with paliperidone with placebo Absolute results not reported	RR 0.90 95% CI 0.35 to 2.27		Not significant
Systematic review	568 people 4 RCTs in this analysis	Mean difference in change from baseline in prolactin (ng/mL), men with paliperidone (3–15 mg/day) with placebo Absolute results not reported	Mean difference 22.12 ng/mL 95% CI 21.34 ng/mL to 22.89 ng/mL	Small effect size	placebo
Systematic review	335 people 4 RCTs in this analysis	Mean difference in change from baseline in prolactin (ng/mL), women with paliperidone (3–15 mg/day) with placebo Absolute results not reported	Mean difference 82.50 ng/mL 95% CI 78.88 ng/mL to 86.13 ng/mL	Effect size not calculated	placebo
Systematic review	592 people 4 RCTs in this analysis	Nausea with paliperidone with placebo Absolute results not reported	RR 0.49 95% CI 0.25 to 0.93	Moderate effect size	paliperidone
Systematic review	1007 people 5 RCTs in this analysis	Mean difference in change from baseline in weight (kg) with paliperidone with placebo Absolute results not reported	Mean difference 0.13 kg 95% CI 0.06 kg to 0.20 kg	Effect size not calculated	placebo
Systematic review	573 people 3 RCTs in this analysis	Mean difference in change from baseline in BMI with paliperidone with placebo Absolute results not reported	Mean difference 0.46 95% CI 0.30 to 0.63	Effect size not calculated	placebo
Systematic review	1680 people 6 RCTs in this analysis	Extrapyramidal symptoms with paliperidone with placebo Absolute results not reported	RR 2.27 95% CI 1.31 to 3.95	Moderate effect size	placebo
Systematic review	1360 people 4 RCTs in this analysis	Hyperkinesia with paliperidone (3–15 mg/day) with placebo Absolute results not reported	RR 1.67 95% CI 0.97 to 2.89		Not significant
Systematic review	1225 people 5 RCTs in this analysis	Hypotonia with paliperidone with placebo Absolute results not reported	RR 3.24 95% CI 1.46 to 7.22	Moderate effect size	placebo
Systematic review	352 people 2 RCTs in this analysis	Tremor with paliperidone with placebo Absolute results not reported	RR 1.36 95% CI 0.75 to 2.47		Not significant
Systematic review	352 people 2 RCTs in this analysis	Akathisia with paliperidone with placebo Absolute results not reported	RR 1.43 95% CI 0.58 to 3.52		Not significant
Systematic review	156 people 2 RCTs in this analysis	Tardive dyskinesia with paliperidone with placebo Absolute results not reported	RR 3.00 95% CI 0.13 to 69.70		Not significant
Systematic review	1032 people 4 RCTs in this analysis	Gynaecomastia, men with paliperidone with placebo Absolute results not reported	RR 0.99 95% CI 0.04 to 23.90		Not significant
Systematic review	1187 people 5 RCTs in this analysis	Impotence, men with paliperidone with placebo Absolute results not reported	RR 0.70 95% CI 0.16 to 3.03		Not significant
Systematic review	938 people 5 RCTs in this analysis	Amenorrhoea/dysmenorrhoea, women with paliperidone with placebo Absolute results not reported	RR 1.46 95% CI 0.31 to 6.92		Not significant
Systematic review	1763 people 5 RCTs in this analysis	Abnormal sexual function with paliperidone with placebo Absolute results not reported	RR 0.61 95% CI 0.12 to 3.11		Not significant
Systematic review	1566 people 5 RCTs in this analysis	Suicide attempt with paliperidone with placebo Absolute results not reported	RR 0.62 95% CI 0.22 to 1.77		Not significant